These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29870791)

  • 1. Advances in treatment formulations for acute myeloid leukemia.
    Briot T; Roger E; Thépot S; Lagarce F
    Drug Discov Today; 2018 Dec; 23(12):1936-1949. PubMed ID: 29870791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of targeted therapy in the management of patients with AML.
    Perl AE
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):54-65. PubMed ID: 29222237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
    DeAngelo DJ; Stein EM; Ravandi F
    Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
    Yamauchi T
    Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
    Ravandi F
    Best Pract Res Clin Haematol; 2014; 27(3-4):241-6. PubMed ID: 25455273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
    Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
    Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach.
    Fernandez HF; Rowe JM
    Curr Opin Hematol; 2010 Mar; 17(2):79-84. PubMed ID: 20087177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel therapies for acute myeloid leukemia based on genomic aberrations].
    Umezawa Y; Kawamata N
    Rinsho Ketsueki; 2019; 60(6):594-599. PubMed ID: 31281150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol.
    Puty TC; Sarraf JS; Do Carmo Almeida TC; Filho VCB; de Carvalho LEW; Fonseca FLA; Adami F
    Syst Rev; 2019 May; 8(1):109. PubMed ID: 31053175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
    Lai C; Bhansali RS; Kuo EJ; Mannis G; Lin RJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390018. PubMed ID: 37155946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A User's Guide to Novel Therapies for Acute Myeloid Leukemia.
    Patel SA; Gerber JM
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):277-288. PubMed ID: 32113891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia.
    Poonia N; Jadhav NV; Mamatha D; Garg M; Kabra A; Bhatia A; Ojha S; Lather V; Pandita D
    Ther Deliv; 2024; 15(11):893-910. PubMed ID: 39268925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
    Murphy T; Yee KWL
    Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
    Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
    Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
    Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
    Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.